Introduction {#Sec1}
============

Gastric cancer is a heterogeneous disease, and its incidence shows wide variation among geographic regions. Although the global incidence of gastric cancer has decreased markedly over the past 40 years, almost 1 million new cases are estimated to have occurred in 2012 \[[@CR1]\]. Gastric cancer remains highly prevalent in eastern Asia (mainly in China) and is also common in central and eastern Europe and in central and South America \[[@CR1]\]. Western Europe and North America are considered low-risk regions \[[@CR2]\], although there has been a steady increase in gastroesophageal junction carcinoma in these geographic regions since the 1970s \[[@CR3]\].

AVAstin in GASTric cancer (AVAGAST) was an international, randomised, phase III study designed to compare the efficacy of bevacizumab plus standard chemotherapy versus placebo plus chemotherapy as first-line treatment for patients with advanced gastric cancer \[[@CR4]\]. In the primary efficacy analysis, the addition of bevacizumab to chemotherapy significantly prolonged progression-free survival and improved overall response rate, but had no significant benefit on the primary study endpoint, overall survival \[[@CR4]\]. Randomization in the AVAGAST trial was stratified by region (Asia Pacific, Europe, pan-America). In pre-planned subgroup analyses, it was evident that efficacy outcomes in both treatment arms varied markedly by region, with patients from the Asia--Pacific region showing no survival benefit from the addition of bevacizumab to chemotherapy, in contrast to patients from other regions \[[@CR4]\]. Furthermore, patients from the Asia--Pacific region who received placebo plus chemotherapy had better outcomes than patients from other regions \[[@CR4]\].

At the time of the study, regional differences in the prognosis of gastric cancer were one of the major clinical questions. The factors influencing observed differences in prognosis were considered to be either tumor biology or the healthcare environment. The effects of tumor biology on outcomes in the AVAGAST study have already been reported \[[@CR5], [@CR6]\], but the impact of the healthcare environment has not been studied. Therefore, we performed a set of exploratory analyses using data from the AVAGAST trial to examine the effect of regional differences in the healthcare environment on study outcomes by investigation of the use of second-line therapy and baseline characteristics. We analyzed data from the placebo group only to exclude the possible effects of bevacizumab. The cutoff date for the primary analysis was November 2009, after a median follow-up of approximately 10 months. The cutoff date for the present analysis was almost 4 years later at the time of trial completion in September 2013.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

AVAGAST was a prospective, randomized, double-blind, placebo-controlled, phase III trial designed to evaluate the efficacy of adding bevacizumab to capecitabine plus cisplatin in the first-line treatment of patients with advanced gastric cancer. The design of AVAGAST has been described in full previously \[[@CR4]\]. The protocol was approved at each participating site by an independent ethics committee or institutional review board. The trial was registered (ClinicalTrials.gov identifier: NCT00548548).

Patients {#Sec4}
--------

Patients with histologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the stomach or gastroesophageal junction who had received no previous treatment for metastatic gastric cancer were eligible. Patients could have measurable or non-measurable disease, provided that it was evaluable according to response evaluation criteria in solid tumors (version 1.0) \[[@CR7]\]. (Neo)adjuvant chemotherapy was allowed if completed within 6 months before randomization, but previous platinum or anti-angiogenic therapy was not permitted.

Randomization and treatment {#Sec5}
---------------------------

Patients were randomly assigned (1:1) to bevacizumab (Avastin) or placebo plus capecitabine or 5-fluorouracil in combination with cisplatin. Bevacizumab 7.5 mg/kg or placebo was administered as an intravenous infusion on day 1, followed by cisplatin 80 mg/m^2^ as an intravenous infusion, then oral capecitabine 1000 mg/m^2^ twice daily on days 1--14 every 3 weeks. Cisplatin was administered for six cycles; capecitabine and bevacizumab were continued until disease progression or unacceptable toxicity occurred. 5-Fluorouracil (800 mg/m^2^/day as a continuous intravenous infusion on days 1--5 every 3 weeks) was administered instead of capecitabine to patients unable to take oral medications. Treatments given after disease progression were recorded.

Assessments {#Sec6}
-----------

Tumor assessments (magnetic resonance imaging and/or computed tomography) were performed within 21 days before randomization and were repeated every 6 weeks for the first year after randomization and every 12 weeks thereafter until disease progression. Survival status was assessed every 3 months after completion of study treatment.

Overall survival, the primary study endpoint, was defined as the time between randomization and death irrespective of cause. Progression-free survival was a secondary endpoint, defined as the time between randomization and first documented disease progression event or death.

Statistical analysis {#Sec7}
--------------------

The data cutoff date for the primary analysis was November 2009, after 517 overall survival events had occurred \[[@CR4]\]. AVAGAST was completed in September 2013; data from this later cutoff were used in the present analysis. All analyses were performed in patients assigned to the placebo plus chemotherapy arm (intention-to-treat population). The present analyses were not previously planned in the study protocol and are exploratory in nature.

Participating countries were divided into four regions: USA and western Europe (Australia, Belgium, France, Germany, Italy, Spain, UK); eastern Europe (Russia) and South America (Brazil, Costa Rica, Peru); Korea and other Asian countries (Korea, China, Singapore, Taiwan); and Japan. Patient baseline characteristics and the proportion of patients who received chemotherapy after disease progression were compared among the four regions. Time-to-event endpoints were analyzed using the Kaplan--Meier method by region. Outcomes for USA/western Europe versus each of the other regions were compared using a Cox proportional hazards model and expressed as hazard ratios with 95% confidence intervals (CIs). A multivariate analysis of overall survival was also performed using Cox proportional hazards regression models with region and other prognostic variables as covariates, and the Wald chi-square test used to test differences between covariates.

Results {#Sec8}
=======

Patient population {#Sec9}
------------------

A total of 387 patients were assigned to the placebo plus chemotherapy arm, of which 81 patients were enrolled from USA/western Europe, 118 patients from eastern Europe/South America, 94 patients from Korea and other locations in Asia, and 94 patients from Japan.

Baseline characteristics by region are presented in Table [1](#Tab1){ref-type="table"}. There were some differences between regions with respect to patient and tumor characteristics at baseline. An Eastern Cooperative Oncology Group (ECOG) performance status of 1 or 2, the presence of liver metastases, and a maximum tumor size ≥ 40 mm were observed most frequently in patients enrolled from eastern Europe/South America and least often in patients from Japan. Liver and peritoneal metastases were each present in approximately 30‒40% of patients in patients from USA/western Europe and eastern Europe/South America, whereas in Asian countries liver metastases were documented in 25‒30% of patients and peritoneal metastases in 50‒55% of patients.Table 1Baseline characteristics by region (placebo plus chemotherapy arm)CharacteristicUSA/western Europe (*n* = 81)Eastern Europe/South America (*n* = 118)Korea and other Asia (*n* = 94)Japan (*n* = 94)SexMale52 (64)80 (68)63 (67)63 (67)Female29 (36)38 (32)31 (33)31 (33)Age (years)\< 6549 (60)92 (78)75 (80)62 (66)≥ 6532 (40)26 (22)19 (20)32 (34)ECOG performance status042 (52)28 (24)36 (38)62 (66)≥ 139 (48)90 (76)58 (62)32 (34)Primary siteStomach52 (64)107 (91)91 (97)88 (94)Gastroesophageal junction29 (36)11 (9)3 (3)6 (6)Disease statusLocally advanced4 (5)4 (3)01 (1)Metastatic77 (95)114 (97)94 (100)93 (99)Liver metastasisYes27 (34)51 (43)25 (27)23 (24)No53 (66)67 (57)69 (73)71 (76)Number of metastatic sites\> 145 (57)80 (70)63 (67)59 (63)≤ 134 (43)35 (30)31 (33)35 (37)Histological type^a^Intestinal39 (48)46 (39)28 (30)22 (23)Diffuse/mixed40 (49)68 (58)52 (55)72 (77)Prior gastrectomyYes16 (20)32 (27)28 (30)31 (33)No65 (80)86 (73)66 (70)63 (67)Prior (neo)adjuvant chemotherapyYes9 (11)3 (3)10 (11)8 (9)No72 (89)115 (97)84 (89)86 (91)Disease measurability (tumor size)^b^Not measurable16 (20)18 (15)27 (29)29 (31)Measurable (\< 40 mm)39 (49)47 (40)48 (51)47 (50)Measurable (≥ 40 mm)25 (31)53 (45)19 (20)18 (19)Peritoneal metastasisYes24 (30)47 (40)49 (52)52 (55)No57 (70)71 (60)45 (48)42 (45)Bone metastasisPresent4 (5)4 (3)3 (3)5 (5)Not present76 (95)114 (97)91 (97)89 (95)Data are expressed as *n* (%)*ECOG* Eastern Cooperative Oncology Group^a^Patients with unknown histological type are excluded^b^One patient from USA/western Europe had a measurable tumour of unknown size

Post-progression chemotherapy {#Sec10}
-----------------------------

A summary of chemotherapeutic agents given after disease progression is provided in Table [2](#Tab2){ref-type="table"}. Subsequent chemotherapy after disease progression was given to 17 patients (14%) enrolled from eastern Europe/South America, 30 (37%) from USA/western Europe, 57 (61%) from Korea and other Asia locations, and 72 (77%) from Japan.Table 2Post-progression chemotherapy for gastric cancer (placebo plus chemotherapy arm)TreatmentUSA/western Europe (*n* = 81)Eastern Europe/South America (*n* = 118)Korea and other Asia (*n* = 94)Japan (*n* = 94)Total30 (37)17 (14)57 (61)72 (77) Paclitaxel321552 Docetaxel1222413 Irinotecan1072232 5-Fluorouracil1463218 S-100914 Capecitabine4220 Methotrexate00212 Folinic acid85265 Cisplatin23107 Oxaliplatin22173Data are expressed as *n* (%) or *n*

Overall survival and progression-free survival {#Sec11}
----------------------------------------------

At the cutoff date, the median duration of follow-up in the placebo plus chemotherapy arm was 9.7 months (range, 0.1--54.5 months). A summary of efficacy by region is presented in Table [3](#Tab3){ref-type="table"}. In the placebo plus chemotherapy arm, a total of 348 patients (90%) had died. The median duration of overall survival was 7.3 months (95% CI, 6.4--8.7) in eastern Europe/South America, 9.1 months (95% CI, 6.9--14.4) in USA/western Europe, 11.6 months (95% CI, 9.1--15.6) in Korea and other Asia, and 14.1 months (95% CI, 10.9--17.6) in Japan. Kaplan--Meier curves for overall survival showed that the prognosis of patients in eastern Europe/South America tended to be worse than in other regions (Fig. [1](#Fig1){ref-type="fig"}a). The hazard ratios for overall survival for each region when compared against USA/western Europe were 1.47 (95% CI, 1.09--1.99) for eastern Europe/South America, 0.91 (95% CI, 0.67--1.25) for Korea and other Asia, and 0.87 (95% CI, 0.64--1.19) for Japan. After adjusting for key prognostic factors (Table [4](#Tab4){ref-type="table"}), the hazard ratios for overall survival for each region when compared against USA/western Europe showed little change \[1.52 (95% CI, 1.08--2.14) for eastern Europe/South America, 0.82 (95% CI, 0.57--1.18) for Korea and other Asia, and 0.81 (95% CI, 0.57--1.14) for Japan\].Table 3Efficacy outcomes by region (placebo plus chemotherapy arm)RegionNumber of eventsMedian, months (95% CI)Hazard ratio^a^ (95% CI)Overall survival USA/western Europe (*n* = 81)729.1 (6.9--14.4)-- Eastern Europe/South America (*n* = 118)1057.3 (6.4--8.7)1.47 (1.09--1.99) Korea and other Asia (*n* = 94)8411.6 (9.1--15.6)0.91 (0.67--1.25) Japan (*n* = 94)8714.1 (10.9--17.6)0.87 (0.64--1.19)Progression-free survival USA/western Europe (*n* = 81)754.4 (4.0--5.7)-- Eastern Europe/South America (*n* = 118)1114.4 (4.0--5.4)1.19 (0.89--1.59) Korea and other Asia (*n* = 94)935.6 (4.8--6.5)1.01 (0.74--1.37) Japan (*n* = 94)925.7 (5.1--7.0)0.96 (0.71--1.31)*CI* confidence interval^a^Compared with USA/western Europe Fig. 1Kaplan--Meier curves by region of (**a**) overall survival and (**b**) progression-free survival. Data are for the placebo plus chemotherapy arm only Table 4Cox proportional hazards analysis of overall survival (placebo plus chemotherapy arm)CovariateHazard ratio (95% CI)*p* valueJapan vs. USA/western Europe0.81 (0.57--1.14)0.2270Korea and other Asia vs. USA/western Europe0.82 (0.57--1.18)0.2936Eastern Europe/South America vs. USA/western Europe1.52 (1.10--2.14)0.0170Sex (female vs. male)1.01 (0.80--1.28)0.9275Age (\< 65 vs. ≥ 65 years)0.90 (0.70--1.16)0.4050ECOG performance status (0 vs. ≥ 1)0.73 (0.57--0.93)0.0116Primary site (gastroesophageal junction vs. stomach)1.11 (0.77--1.60)0.5754Disease status (locally advanced vs. metastatic)2.81 (1.33--5.92)0.0067Liver metastases (no vs. yes)0.71 (0.53--0.94)0.0161Histological type (diffuse vs. mixed)0.98 (0.62--1.57)0.9434Histological type (intestinal vs. mixed)0.75 (0.47--1.22)0.2473Prior gastrectomy (no vs. yes)1.61 (1.23--2.11)0.0006Prior (neo)adjuvant therapy (no vs. yes)0.74 (0.49--1.12)0.1510Tumor size (\< 40 mm vs. not measurable)1.17 (0.86--1.58)0.3251Tumor size (≥ 40 mm vs. not measurable)1.04 (0.74--1.46)0.8259Bone metastases (no vs. yes)0.45 (0.25--0.78)0.0050Peritoneal metastases (no vs. yes)0.55 (0.42--0.73)\< 0.0001Number of metastatic sites (\> 1 vs. ≤ 1)0.96 (0.73--1.26)0.7584*ECOG* Eastern Cooperative Oncology Group

In the placebo plus chemotherapy arm, a total of 371 patients (96%) had progression-free survival events. Median progression-free survival by region was 4.4 months (95% CI, 4.0--5.4) in eastern Europe/South America, 4.4 months (95% CI, 4.0--5.7) in USA/western Europe, 5.6 months (95% CI, 4.8--6.5) in Korea and other Asia, and 5.7 months (95% CI, 5.1--7.0) in Japan. Kaplan--Meier curves of progression-free survival by region indicated that the prognosis of patients in eastern Europe/South America tended to be worse than in other regions (Fig. [1](#Fig1){ref-type="fig"}b). The hazard ratios for progression-free survival for each region compared against USA/western Europe were 1.19 (95% CI, 0.89--1.59) for eastern Europe/South America, 1.01 (95% CI, 0.74--1.37) for Korea, and other Asia and 0.96 (95% CI, 0.71--1.31) for Japan.

Discussion {#Sec12}
==========

The AVAGAST trial was designed to investigate the efficacy of adding a targeted agent---bevacizumab---to standard first-line chemotherapy for patients with advanced gastric cancer. Pre-planned subgroup analyses revealed marked differences between regions in overall survival, estimates that were viewed as robust because 60--70% of patients had died at the time of analysis \[[@CR4]\]. The present set of exploratory analyses was performed to better understand the reasons for the regional differences observed in the AVAGAST study.

In our analyses, we observed that patients enrolled in eastern Europe/South America had the shortest median overall survival (7.3 months), followed by patients from USA/western Europe (9.1 months), with patients from both Asian regions showing the longest overall survival times (11.6--14.1 months). The same regional ranking was apparent in other study parameters, i.e. some baseline characteristics and the use of post-progression chemotherapy. We suggest that these differences may have contributed to the regional differences in survival outcomes.

In AVAGAST, the use of further lines of chemotherapy after disease progression was lowest in eastern Europe/South America (14% of patients), followed by USA/western Europe (37%), with the highest usage evident in Korea (61%) and Japan (77%). The inverse relationship between the use of post-progression chemotherapy and overall survival suggests that this was a likely contributing factor to the different survival outcomes between regions. Similar observations have been made in the RAINBOW trial, where uptake of chemotherapy after discontinuation of study treatment was also higher in patients enrolled from Asian centers (67% vs. 37% of patients from other regions), along with improved overall survival (median, 10.5 months in Asia vs. 5.9 months in other regions) \[[@CR8]\].

A possible reason for the differential uptake of second-line therapy is that there was no clear evidence to support the use of chemotherapy after disease progression yet there was considerable risk of toxicity. In the intervening years, several phase III randomised trials have demonstrated that second-line chemotherapeutic \[[@CR9]--[@CR12]\] or targeted agents \[[@CR8], [@CR13]\] significantly improve overall survival in patients with gastroesophageal cancer compared with best supportive care/active symptom control. These trials have established the role of second-line therapy in patients with gastroesophageal cancer, a practice that is now endorsed in major European \[[@CR14]\] and US \[[@CR15]\] clinical practice guidelines. Other possible reasons to explain the differential use of post-progression chemotherapy may include differences in health insurance between countries. Few drugs are reimbursed for second and later lines of therapy in patients with gastric cancer in eastern Europe and South America, whereas more drugs are reimbursed in Japan. Not all patients are physically fit enough to be offered second-line therapy. In our analysis of patients' baseline characteristics, the likelihood of a poor ECOG performance status was greatest in eastern Europe/South America and lowest in the Asian regions, which may also have influenced the choice of therapy.

We also identified differences in baseline tumor characteristics among regions. Patients in eastern Europe/South America were more likely to have liver metastases and measurable disease ≥ 40 mm at baseline than patients enrolled from other regions; patients from both Asian regions had the lowest rates for both parameters. Conversely, peritoneally limited disease was more common in Asian countries. These findings are consistent with an earlier diagnosis of gastric cancer and are probably linked to the screening programs that are in place in some Asian countries. Japan and Korea have ongoing nationwide screening programs, both of which were in place before AVAGAST started \[[@CR16]--[@CR19]\]. Further, Taiwan has a screening program for a high-risk population (on Matzu Island) \[[@CR18], [@CR19]\]. A secondary prevention program (i.e., upper gastrointestinal endoscopy for all symptomatic cases) in patients aged ≥ 40 years was also established in Chile in 2006 \[[@CR20]\]. Other countries and regions with a lower risk of gastric cancer do not have screening programs because they are not likely to be cost effective. In our analysis, earlier detection of primary tumors in countries with screening programs may have led to earlier identification of metastatic disease and an apparently longer overall survival (i.e., lead-time bias) versus regions without screening programs.

Molecular heterogeneity may also underpin the findings from our study, although gene expression profiling was not performed in AVAGAST. The Cancer Genome Atlas Research Network reported differences in pathway-level gene expression between patients from eastern Asia compared with patients from other regions \[[@CR21]\]. Another recent study revealed that tumors from Asian and non-Asian patients exhibited distinct differences in gene signatures related to inflammation and immunity, with T-cell pathways being preferentially associated with gastric cancers in non-Asian patients compared with Asian patients \[[@CR22]\]. Further, the Asian Cancer Research Group used gene expression data to identify four distinct molecular subtypes that were associated with disease progression and prognosis \[[@CR23]\]. Notably, the proportions of patients with these tumor subtypes varied according to geographic region \[[@CR23]\]. It is likely that such studies will provide further insight into tumor characteristics and their implications for prognosis.

It is interesting to note that the overall survival of patients with advanced gastric cancer in clinical trials performed in the 1990s was relatively similar among regions (Table [5](#Tab5){ref-type="table"}). It seems unlikely that major changes in biological characteristics of gastric tumors have developed in the past decade to explain the regional differences in AVAGAST. Rather, we suggest that differential changes in clinical practice (i.e., improved early diagnosis in high-risk countries, use of second-line therapy) may have had a greater effect than biological differences. It is also interesting to note that data from more recent studies (Table [5](#Tab5){ref-type="table"}) show gradual improvements in overall survival in non-Asian regions and a trend toward convergence of survival times.Table 5Overall survival in phase III trials of first-line platinum/fluoropyrimidine-based regimens in advanced gastric cancerReferencesRegion/countryEnrollment periodTreatmentNo. of patientsMedian overall survival, monthsKim et al. \[[@CR24]\]Korea1986--1990FP1038.5Vanhoefer et al. \[[@CR25]\]Europe1991--1995FP1347.2Ohtsu et al. \[[@CR26]\]Japan1992--1997FP1057.1Van Cutsem et al. \[[@CR27]\]International1999--2003FP2308.6Dank et al. \[[@CR28]\]International2000--2002FP1658.7Cunningham et al. \[[@CR29]\]UK/Australia2000--2005EPF2639.9EPC2509.9EOF2459.3EOC24411.2Koizumi et al. \[[@CR30]\]Japan2002--2004SP14813.0Kang et al. \[[@CR31]\]International2003--2005FP1568.9CP16010.4Ajani et al. \[[@CR32]\]USA/Europe/South America2005--2007SP5278.6FP5267.9Ohtsu et al. \[[@CR4]\]International2007--2008CP38710.1Lordick et al. \[[@CR33]\]International2008--2010CP45510.7Waddell et al. \[[@CR34]\]UK2008--2011EOC27511.3Kim et al. \[[@CR35]\]Korea2009--2012CP12411.5Shen et al. \[[@CR36]\]China2009--2010CP10211.4Yamada et al. \[[@CR37]\]Japan2010--2011SP32413.1SO31814.1Only data for the platinum/fluoropyrimidine-containing study arms are shown*C* capecitabine, *E* epirubicin, *F* 5-fluorouracil, *O* oxaliplatin, *P* cisplatin, *S* S-1

The analyses reported in the present paper were exploratory in nature and hypothesis generating only but may assist with the design of future international trials in advanced gastric cancer. We believe that there are no regional differences in drug efficacy in general. If regional differences related to other factors exist, they should be considered and kept to a minimum by appropriate study design, not only with regard to stratification factors but also with the statistical design based on the assumed overall survival of the patient population included in the study.

In conclusion, regional differences in the healthcare environment (i.e., use of second-line chemotherapy and screening programs) may have contributed to the differences in prognosis observed in the AVAGAST study. As second-line therapy for metastatic disease and screening programs in high-risk populations become more widely used, differences in outcomes in patients with advanced gastric cancer may diminish among regions.
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